Related Experiment Video

Updated: Jun 22, 2026

A 96 Well Microtiter Plate-based Method for Monitoring Formation and Antifungal Susceptibility Testing of Candida albicans Biofilms
07:19

A 96 Well Microtiter Plate-based Method for Monitoring Formation and Antifungal Susceptibility Testing of Candida albicans Biofilms

Published on: October 21, 2010

[Micafungin for the treatment of neonatal invasive candidiasis]

María Elena Infante-López1, Pablo Rojo-Conejo

  • 1Servicio de Neonatología, Hospital Universitario 12 de Octubre, Madrid, España. eleninf@hotmail.com

Revista Iberoamericana De Micologia
|May 26, 2009
PubMed
Abstract

Insights

Micafungin offers a promising treatment for invasive candidiasis in neonates, showing broad-spectrum activity and minimal toxicity. Further clinical studies are needed to confirm its efficacy and safety in this vulnerable population.

Area of Science:

  • Neonatal Intensive Care Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Deep fungal infections caused by Candida species pose a significant clinical challenge in neonatal intensive care units.
  • Increasing prevalence and high mortality rates associated with Candida infections persist despite advancements in neonatal patient management.

Purpose of the Study:

  • To evaluate the therapeutic application of micafungin for treating invasive candidiasis in neonates.

Main Methods:

  • A comprehensive review of biomedical databases, including Medline and EMBASE, was conducted.

Main Results:

  • Micafungin, a novel echinocandin, exhibits broad-spectrum activity against Candida albicans and non-albicans species.
  • It demonstrates limited drug interactions and a favorable safety profile, making it a potential option for invasive candidiasis, excluding meningitis, endocarditis, and endophthalmitis.

Conclusions:

  • While approved for pediatric use, clinical experience with micafungin in neonates remains limited.
  • Additional clinical studies are essential to fully establish the efficacy and safety of micafungin for neonatal invasive candidiasis.

More Related Videos

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...